Jean Hailes for Women's Health will receive $8.4M from the Australian Government to ensure every woman and girl in Australia can access trusted, evidence-based health information. Jean Hailes currently reaches 2.2 million website visitors and 6.6 million women on social media. The funding will also support research, health professional education, the annual Women's Health Week and the National Women's Health Survey. It builds on the government's broader $800M women's health package.
“We are deeply grateful to the Albanese Government for this investment in women’s health. This funding means we can continue to reach millions of women in Australia with the trusted, evidence-based health information they deserve. Every woman, regardless of where she lives or her background, should be able to access quality health information at every stage of her life, and this support helps make that possible.”
— Sarah White, CEO, Jean Hailes
The newly formed Australian medtech company has launched with US$13.75M (AUD $19M) in financing led by SPRIM Global Investments, securing an exclusive global licence from Toronto-based EBT Medical for the NiNA System - a wearable neuromodulation device that targets the saphenous nerve to treat overactive bladder without drugs or surgery. OAB affects an estimated 550 million patients worldwide, predominantly women. Funding will support an IDE application and global commercialisation.
"SPRIM is excited to announce the establishment of NinaMED as a new Australian medical device company and to have led this financing. The NiNA System® represents a compelling and differentiated solution in the large and growing OAB market. We look forward to supporting NinaMED as it advances NiNA towards worldwide commercialisation,"
— Michael Shleifer, SPRIM Global Investments
The FDA has approved a new Enhertu-based regimen for adults with stage 2 or 3 HER2-positive breast cancer - giving patients a more effective, less toxic option before surgery. In the DESTINY-Breast11 trial, patients on the Enhertu sequence achieved a pathological complete response rate of 67.3% versus 56.3% on the traditional chemotherapy regimen, with half the rate of serious side effects. The approval also covers patients with residual disease after surgery. One oncologist called it a "win-win."
🔗 https://www.curetoday.com/view/fda-approves-enhertu-regimen-for-her2-positive-early-breast-cancer
Nutraceuticals manufacturer Healthy Extracts has acquired Imaraïs Beauty, a women's wellness and beauty gummy brand co-founded by fitness influencer Sommer Ray and supplement entrepreneur Aaron Hefter. The deal lifts the company's 2026 annualised revenue run rate by 20% to $24M. Imaraïs products are sold at Target, Ulta Beauty, Nordstrom and Sprouts across the US. Ray - who has 35.6 million social media followers - becomes a major shareholder and stays on as the face of the brand.
Dr. Sandra Orsulic of UCLA's David Geffen School of Medicine has received two federal grants totalling nearly $1.9M to tackle two of the biggest challenges in ovarian cancer: preventing recurrence after surgery, and developing more accessible tools for personalised treatment decisions. One study investigates whether surgery itself can inadvertently help cancer spread - and how to stop it. The other focuses on making tumour biology analysis more practical for clinics worldwide.
“Ovarian cancer remains one of the deadliest gynecologic cancers, in part because many patients are diagnosed at advanced stages and tumors frequently recur after treatment. We hope these newly funded studies will help address critical gaps in both the treatment of recovery of this disease.”
— Dr. Sandra Orsulic, Professor in the Departments of Obstetrics & Gynecology, David Geffen School of Medicine
🔗 https://www.eurekalert.org/news-releases/1128866
W. Group has launched the Women's Sport Summit - a new industry conference for the women's sport ecosystem, co-located with Women's Health Week Europe at Emirates Stadium, London on October 6-7, 2026. Born from a conversation at WHW Europe 2025, the Summit will focus on the commercial potential of women's sport, bringing together stakeholders from both the health and sport industries under one roof for the first time.
"Our model at W Group is built on a clear thesis. Overlooked, underserved, and underinvested markets - once properly understood - can become some of the most commercially compelling opportunities available. Women's sport is exactly that. The audiences now exist, capital is entering, and deals are being done. What the industry needs now is the right environment to accelerate that. Women's Sport Summit is that environment."
— Nathan Edwards, Founder, W. Group
🔗 https://womenshealthweek.com/post/w-group-announces-the-womens-sport-summit
